SPOTLIGHT: AstraZeneca wants FDA ad review


AstraZeneca is lobbying Congress for FDA review of television ads. Last fall lawmakers created a program that would require up-front scrutiny of DTC ads, but didn't give the FDA authority to collect and spend industry fees to fund it. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.